Advertisement
Canadian Journal of Cardiology

Erratum

    Published:August 27, 2015DOI:https://doi.org/10.1016/j.cjca.2015.06.014
        In the article, “The 2014 Canadian Cardiovascular Society Heart Failure Management Guidelines Focus Update: Anemia, Biomarkers, and Recent Therapeutic Trial Implications” by Moe et al., published in the January issue (Can J Cardiol 2015; 31:3-16), there is an error on page 12. The recommendation on combined angiotensin/neprilysin inhibition in HFrEF should state an EF of ≤ 40%. A corrected recommendation is provided here.
        • 1.
          We recommend that in patients with mild to moderate HF, an EF ≤ 40%, an elevated NP level or hospitalization for HF in the past 12 months, a serum potassium < 5.2 mmol/L, and an eGFR ≥ 30 mL/min and treated with appropriate doses of guideline-directed medical therapy should be treated with LCZ696 in place of an ACE inhibitor or an angiotensin receptor blocker, with close surveillance of serum potassium and creatinine (Conditional Recommendation; High-Quality Evidence).

        Linked Article